Page last updated: 2024-08-26

fulvestrant and epothilone a

fulvestrant has been researched along with epothilone a in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Miles, DW	1

Other Studies

2 other study(ies) available for fulvestrant and epothilone a

Article	Year
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. Breast cancer research : BCR, 2009, Volume: 11, Issue:4 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytotoxins; Drug Carriers; Drug Delivery Systems; Drug Resistance, Neoplasm; Epothilones; Estradiol; Female; Fulvestrant; Humans; Intracellular Signaling Peptides and Proteins; Nanoparticles; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Salvage Therapy; TOR Serine-Threonine Kinases	2009

Article

Year

Identifying off-target effects and hidden phenotypes of drugs in human cells.

Nature chemical biology, 2006, Volume: 2, Issue:6

Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.

Breast cancer research : BCR, 2009, Volume: 11, Issue:4

Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytotoxins; Drug Carriers; Drug Delivery Systems; Drug Resistance, Neoplasm; Epothilones; Estradiol; Female; Fulvestrant; Humans; Intracellular Signaling Peptides and Proteins; Nanoparticles; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Salvage Therapy; TOR Serine-Threonine Kinases

2009